Issued Patents All Time
Showing 1–15 of 15 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12312409 | Bispecific CD137-binding antibodies for T-cell activation | Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang | 2025-05-27 |
| 12304961 | PD-L1 and OX40 binding proteins for cancer regulation | Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Hung-Tsai Kan, Ting-Yi Chang +1 more | 2025-05-20 |
| 11780922 | Bifunctional proteins combining checkpoint blockade for targeted therapy | Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang | 2023-10-10 |
| 11725058 | CD137 antibodies for T-cell activation | Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang | 2023-08-15 |
| 11643470 | PD-L1 and OX40 binding proteins for cancer Regulation | Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Hung-Tsai Kan, Ting-Yi Chang +1 more | 2023-05-09 |
| 11518984 | Protein inhibitors to complement and VEGF pathways and methods of use thereof | Huang-Tsu Chen | 2022-12-06 |
| 11299531 | Fusion protein comprising a ligand binding domain of VEGF and PDGF | Kevin Zen, Pei-Tzu Wu, Huang-Tsu Chen, Jiun-Shyang Leou, Ching-Hsuan Hsu | 2022-04-12 |
| 9988611 | Protein inhibitors to complement and VEGF pathways and methods of use thereof | Huang-Tsu Chen | 2018-06-05 |
| 8178346 | GPCR expression vector | Helena Mancebo, Samuel X. Li, Jianfu L. Wang | 2012-05-15 |
| 8148110 | Detection of molecular interactions by β-lactamase reporter fragment complementation | Helen M. Blau, Robert Balint, Thomas S. Wehrman | 2012-04-03 |
| 7981843 | Antibody specificity transfer using minimal essential binding determinants | Peter Flynn, Kenneth Luehrsen, Robert Balint, Christopher R. Bebbington, Geoffrey T. Yarranton | 2011-07-19 |
| 7781209 | GPCR-expressing cell lines | Helena Mancebo, Samuel X. Li, Jianfu L. Wang | 2010-08-24 |
| 7544477 | Circularly permutated, interaction-activated proteins | Robert Balint | 2009-06-09 |
| 7432063 | Methods for affinity maturation | Robert Balint | 2008-10-07 |
| 7335478 | Reactivation-based molecular interaction sensors | Robert Balint | 2008-02-26 |